Vaccine Adjuvants Market to Reach $1.5Billion Globally, By 2032 at 4% CAGR: Allied Market Research

Risingvaccine development activities, increasing prevalence of infectious diseases, and advancements in immunology are driving the market growth.

Wilmington, New Castle, Delaware, March 12, 2024 (GLOBE NEWSWIRE) — Allied Market Research published a report, titled, “Vaccine Adjuvants Market by Product Type (Immunostimulants and Vehicles & Mucosal Adjuvants), Disease (Infectious Diseases and Cancer), and Application (Research and Commercial): Global Opportunity Analysis and Industry Forecast, 2023–2032”. According to the report, the vaccine adjuvants market was valued at $1 billion in 2022 and is estimated to reach $1.5 billion by 2032, exhibiting a CAGR of 4% from 2023 to 2032. 

Prime Determinants of Growth 

Growing healthcare infrastructure, rise in prevalence of disease conditions that require effective treatment, and growing awareness regarding the use of vaccine adjuvants in vaccine for research as well as commercial utilization are the factors that drive the growth of the global vaccine adjuvants market. However, high development cost and stringent regulatory requirements hinder the market growth. On the contrary, a rise in healthcare expansion and the growing infectious disease load are expected to offer remunerative opportunities for the vaccine adjuvants market during the forecast period. 

Request Sample of the Report on Vaccine Adjuvants Market Forecast 2032 

Report coverage & details: 

Report Coverage  Details 
Forecast Period  2023–2032 
Base Year  2022 
Market Size In 2022  $1 Billion 
Market Size In 2032  $1.5 Billion 
CAGR  4.00% 
No. Of Pages In Report  280 
Segments Covered  Type, Disease, Application, And Region 
Drivers   Increase In Vaccine Development Activities 
Surge In the Number of Infectious Diseases 
Government Initiatives and Funding 
Opportunities  Growing Initiatives for Market Expansion 
Restraints  High Developmental Cost 


Want to Explore More, Connect to our Analyst – 

Recession Scenario 

  • During a recession, the impact on the healthcare industry, including vaccine adjuvants, has  significantly affected the market in a moderately negative stance. 
  • The economic downturns may hinder technology investment. However, the growing infectious disease load among the global population and the rise in commercial as well as research utilization of adjuvants can drive interest in the vaccine adjuvants market.  

The immunostimulants segment to maintain its lead position during the forecast period 

Based on type, the immunostimulants segment dominated the market in 2022, accounting for more than half of the global vaccine adjuvants market. This is attributed to wide availability of vaccine adjuvants in the commercially available products. Also to boost the body’s immune response to vaccines, immunostimulants are preferred, and development of innovative drug delivery systems further drives the segment growth.  

The infectious disease segment to maintain its lead position during the forecast period 

Based on disease, the infectious disease segment dominated the market in 2022, accounting for more than three-fourths of the global vaccine adjuvants market, as numerous people are affected by infectious diseases, which frequently have high incidence rates. As a result, there is a sizable market for adjuvanted vaccines against infectious pathogens. Adjuvants are essential for increasing the vaccinations’ effectiveness and increasing their desirability for research and development as well as for commercialization. 

The commercial segment to maintain its lead position during the forecast period 

Based on application, the commercialsegment dominated the market in 2022, accounting almost three-fourths of the global vaccine adjuvants market, mainly due to the availability of various commercially available vaccines for varied applications, and also the segment is anticipated to grow with the fastest CAGR owing to high prevalence of infectious diseases, thus further boosting the growth of the segment. 

North America to maintain its dominance by 2032 

Based on region, North America held the highest market share in terms of revenue in 2022, accounting for almost two-fourths of the global vaccine adjuvants market, owing to presence of well-developed healthcare industry. In addition, the growing focus of key players on R&D contributes to the formulation of innovative vaccine adjuvants; thereby driving the market growth in the region. However, the Asia-Pacific segment is projected to register highest CAGR of 4.8% during the forecast period owing to increase in the number of infectious diseases leading to a surge in the patient populations and improving healthcare infrastructure in the region for research and development purposes. 

For Procurement Information – 

Leading Market Players:  

  • Adjuvatis 
  • Dynavax Technologies Corporation 
  • GSK 
  • Croda International 
  • Novovax 
  • Agenus Inc 
  • Invivogen 
  • SPI Pharma 
  • Aurorium  

The report provides a detailed analysis of these key players of the global vaccine adjuvants market. These players have adopted different strategy such as partnership and business expansion to increase their market share and maintain dominant shares in different regions. The report is valuable in highlighting business performance, operating segments, product portfolio, and strategic moves of market players to showcase the competitive scenario. 

AVENUE- A Subscription-Based Library (Premium on-demand, subscription-based pricing model) Offered by Allied Market Research: 

AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get an online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports. 

Get an access to the library of reports at any time from any device and anywhere. For more details, follow the link: 

About Allied Market Research: 

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI. 

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.  

David Correa 

1209 Orange Street, 

Corporation Trust Center, 

Wilmington, New Castle, 

Delaware 19801 USA. 

Toll Free: +1-800-792-5285 

Int’l: +1-503-894-6022 

UK: +44-845-528-1300 

Hong Kong: +852-301-84916 

India (Pune): +91-20-66346060 

Fax: +1-855-550-5975   


Follow Us on: LinkedIn Twitter 

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. IndiaShorts takes no editorial responsibility for the same.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Privacy & Cookies Policy